R&D News | pharmaphorum

News

Chasing $80bn sales target, AZ unveils $3.5bn US investment

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end

News

23andMe ends drug development and slashes staff

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.

News

Schizophrenia highlighted in a list of definitions of disorders

Advantage BMS as AbbVie drug fails schizophrenia trials

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

News

J&J bids to add smouldering myeloma to Darzalex label

Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t

News

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.

News

Scientist in a laboratory with sequencer

NHS Wales partners with Illumina on genomics drive

Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.

Chasing $80bn sales target, AZ unveils $3.5bn US investment

23andMe ends drug development and slashes staff

Advantage BMS as AbbVie drug fails schizophrenia trials

J&J bids to add smouldering myeloma to Darzalex label

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

NHS Wales partners with Illumina on genomics drive

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks